126 related articles for article (PubMed ID: 8100680)
1. Proliferative activity in non-Hodgkin's lymphomas. A comparison of the bromodeoxyuridine labeling index with PCNA immunostaining and quantitative image analysis.
Sebo TJ; Roche PC; Witzig TE; Kurtin PJ
Am J Clin Pathol; 1993 Jun; 99(6):668-72. PubMed ID: 8100680
[TBL] [Abstract][Full Text] [Related]
2. MIB-1, Ki67, and PCNA scores and DNA flow cytometry in intermediate grade malignant lymphomas.
Pich A; Ponti R; Valente G; Chiusa L; Geuna M; Novero D; Palestro G
J Clin Pathol; 1994 Jan; 47(1):18-22. PubMed ID: 7907607
[TBL] [Abstract][Full Text] [Related]
3. Quantitative analysis of cellular proliferative activity in 35 T-cell non-Hodgkin's lymphomas. Use of proliferating cell nuclear antigen and Ki-67 (MIB-1) antibodies and nucleolar organizer regions.
Caulet-Maugendre S; Patey M; Granier E; Joundi A; Gentile A; Caulet T
Anal Quant Cytol Histol; 1996 Oct; 18(5):337-44. PubMed ID: 8908304
[TBL] [Abstract][Full Text] [Related]
4. DNA image cytometry and the expression of proliferative markers (proliferating cell nuclear antigen and Ki67) in non-Hodgkin's lymphomas.
Czader M; Porwit A; Tani E; Ost A; Mazur J; Auer G
Mod Pathol; 1995 Jan; 8(1):51-8. PubMed ID: 7731942
[TBL] [Abstract][Full Text] [Related]
5. p53, c-myc p62 and proliferating cell nuclear antigen (PCNA) expression in non-Hodgkin's lymphomas.
Korkolopoulou P; Oates J; Kittas C; Crocker J
J Clin Pathol; 1994 Jan; 47(1):9-14. PubMed ID: 7907610
[TBL] [Abstract][Full Text] [Related]
6. Cellular proliferation in prostatic adenocarcinoma as assessed by bromodeoxyuridine uptake and Ki-67 and PCNA expression.
Cher ML; Chew K; Rosenau W; Carroll PR
Prostate; 1995 Feb; 26(2):87-93. PubMed ID: 7855002
[TBL] [Abstract][Full Text] [Related]
7. A comparative assessment of proliferating cell nuclear antigen, c-myc p62, and nucleolar organizer region staining in non-Hodgkin's lymphomas: a histochemical and immunohistochemical study of 200 cases.
Korkolopoulou P; Patsouris E; Pangalis G; Tsenga A; Elemenoglou J; Thomas-Tsangli E; Spandidos D; Kittas C
Hum Pathol; 1993 Apr; 24(4):371-7. PubMed ID: 7684020
[TBL] [Abstract][Full Text] [Related]
8. Correlation between PCNA and AgNOR scores in non-Hodgkin's lymphomas using sequential staining technique.
Smith FG; Murray PG; Crocker J
J Clin Pathol; 1993 Jan; 46(1):28-31. PubMed ID: 8094401
[TBL] [Abstract][Full Text] [Related]
9. Assessment of potential doubling time (Tpot), argyrophilic nucleolar organizer regions (AgNOR), and proliferating cell nuclear antigen (PCNA) as predictors of therapy response in canine non-Hodgkin's lymphoma.
Vail DM; Kisseberth WC; Obradovich JE; Moore FM; London CA; MacEwen EG; Ritter MA
Exp Hematol; 1996 Jun; 24(7):807-15. PubMed ID: 8647231
[TBL] [Abstract][Full Text] [Related]
10. Proliferating cell nuclear antigen (PCNA) in non-Hodgkin's lymphomas: correlation with working formulation and Kiel classification in formalin-fixed paraffin-embedded material.
Rabenhorst SH; Burini RC; Schmitt FC
Pathology; 1996 Jan; 28(1):12-6. PubMed ID: 8714262
[TBL] [Abstract][Full Text] [Related]
11. Proliferating cell nuclear antigen (PCNA) immunolocalization in paraffin sections: an index of cell proliferation with evidence of deregulated expression in some neoplasms.
Hall PA; Levison DA; Woods AL; Yu CC; Kellock DB; Watkins JA; Barnes DM; Gillett CE; Camplejohn R; Dover R
J Pathol; 1990 Dec; 162(4):285-94. PubMed ID: 1981239
[TBL] [Abstract][Full Text] [Related]
12. The proliferative fraction in lymph nodes: a comparison of proliferating cell nuclear antigen morphometry to flow cytometry.
Krauss JS; Pantazis CG; Chandler FW
Ann Clin Lab Sci; 1992; 22(3):189-96. PubMed ID: 1354428
[TBL] [Abstract][Full Text] [Related]
13. Proliferating cell nuclear antigen (PCNA) immunostaining as an alternative to bromodeoxyuridine (BrdU) immunostaining for brain tumours in paraffin embedded sections.
Sasaki A; Naganuma H; Kimura R; Isoe S; Nakano S; Nukui H; Suzuki K; Kawaoi A
Acta Neurochir (Wien); 1992; 117(3-4):178-81. PubMed ID: 1357920
[TBL] [Abstract][Full Text] [Related]
14. Comparative analysis of proliferating cell nuclear antigen, bromodeoxyuridine, and mitotic index in uveal melanoma.
Ghazvini S; Kroll S; Char DH; Frigillana H
Invest Ophthalmol Vis Sci; 1995 Dec; 36(13):2762-7. PubMed ID: 7499099
[TBL] [Abstract][Full Text] [Related]
15. Proliferating cell nuclear antigen (PCNA) as a prognostic factor in non-Hodgkin's lymphoma.
Klemi PJ; Alanen K; Jalkanen S; Joensuu H
Br J Cancer; 1992 Oct; 66(4):739-43. PubMed ID: 1358164
[TBL] [Abstract][Full Text] [Related]
16. Comparison of brain tumor growth kinetics by proliferating cell nuclear antigen (PCNA) and bromodeoxyuridine (BrdU) labeling.
Lee KS; Yang WI
Yonsei Med J; 1992 Sep; 33(3):265-71. PubMed ID: 1363339
[TBL] [Abstract][Full Text] [Related]
17. Growth fraction in centrocytic and follicular center cell lymphomas: assessment in paraffin sections with a proliferating cell nuclear antigen antibody and morphometric correlates.
Swerdlow SH; Westermann CD; Pelstring RJ; Saboorian MH; Williams ME
Hum Pathol; 1993 May; 24(5):540-6. PubMed ID: 7684024
[TBL] [Abstract][Full Text] [Related]
18. Rapid S-phase determination of non-Hodgkin's lymphomas with the use of an immunofluorescence bromodeoxyuridine labeling index procedure.
Witzig TE; Gonchoroff NJ; Greipp PR; Katzmann JA; Stenson MJ; Habermann TM; Colgan JP; Therneau TM; Banks PM
Am J Clin Pathol; 1989 Mar; 91(3):298-301. PubMed ID: 2646907
[TBL] [Abstract][Full Text] [Related]
19. Growth fraction estimation of malignant lymphomas in formalin-fixed paraffin-embedded tissue using anti-PCNA/Cyclin 19A2. Correlation with Ki-67 labeling.
Kamel OW; LeBrun DP; Davis RE; Berry GJ; Warnke RA
Am J Pathol; 1991 Jun; 138(6):1471-7. PubMed ID: 1675840
[TBL] [Abstract][Full Text] [Related]
20. Comparison of bromodeoxyuridine and proliferating cell nuclear antigen labeling in gastric carcinoma.
Kang SM; Kim WH; Kim CW; Kim YI
J Korean Med Sci; 1994 Feb; 9(1):16-20. PubMed ID: 7915118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
